To highlight the impact of co-pathologies in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) on clinical progression and diagnosis, emphasizing their significance in treatment strategies.
Key Findings:
Patients with both AD and LB co-pathology exhibited more rapid cognitive decline compared to those with AD alone.
44% of patients initially diagnosed with AD, who were negative for AD biomarkers but positive for LB biomarkers, had their diagnoses revised to dementia due to other aetiology.
Patients with LB pathology alone had less overall cognitive impairment but more specific deficits in executive function and visuospatial skills.
Interpretation:
Co-pathologies significantly influence the clinical course of AD and DLB, suggesting that diagnostic boundaries should be reconsidered to reflect underlying pathological contributions, which may enhance treatment approaches.
Limitations:
The study primarily focused on a specific cohort, which may limit generalizability to broader populations.
Longitudinal data may not capture all variations in disease progression, potentially affecting the robustness of findings.
Conclusion:
Understanding co-pathologies is crucial for accurate diagnosis and potential therapeutic interventions, as each pathological accumulation may serve as a target for treatment, guiding future research.
